PE20051171A1 - Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo - Google Patents
Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitriloInfo
- Publication number
- PE20051171A1 PE20051171A1 PE2005000182A PE2005000182A PE20051171A1 PE 20051171 A1 PE20051171 A1 PE 20051171A1 PE 2005000182 A PE2005000182 A PE 2005000182A PE 2005000182 A PE2005000182 A PE 2005000182A PE 20051171 A1 PE20051171 A1 PE 20051171A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- methyl
- imidazol
- carbonitrile
- optionally substituted
- Prior art date
Links
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical group C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 title abstract 4
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 7
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- -1 PYRIMIDINYL Chemical class 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical class N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS 3-QUINOLINCARBONITRILO DE FORMULA (I), EN DONDE Ar ES CICLOALQUILO(C3-C7), PIRIDINILO, PIRIMIDINILO O FENILO, OPCIONALMENTE SUSTITUIDOS POR HALOGENO, ALQUILO(C1-C6), ENTRE OTROS, O ES UN RADICAL -A'-T-L, EN DONDE A' ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO; T ESTA SUSTITUIDO EN UN C DEL FENILO CON -S(CH2)m-, U -O(CH2)m; L ES IMIDAZOL OPCIONALMENTE SUSTITUIDO COM METILO, FENILO, ENTRE OTROS; R1 Y R4 SON INDEPENDIENTEMENTE H; R2 ES H, ALCOXI(C1-C4), F, NITRO; R3 ES PIPERIDINA O DIAZEPAN OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; X ES NH, O, S O NR. SON COMPUESTOS PREFERIDOS: 4-({3-CLORO-4-[(1-METIL-1H-IMIDAZOL-2-IL)TIO]FENIL]AMINO)-6-METOXI-7-(4-PIRROLIDIN-1-IL-PIPERIDIN-1-IL)QUINOLIN-3-CARBONITRILO, 4-({3-CLORO-4-[(1-METIL-1H-IMIDAZOL-2-IL)TIO]FENIL}AMINO)-6-METOXI-7-(4-METIL-PIPERAZIN-1-IL)QUINOLIN-3-CARBONITRILO, 4-({3-CLORO-4-[(1-METIL-1H-IMIDAZOL-2-IL)TIO]FENIL}AMINO)-6-METOXI-7-PIPERAZIN-1-ILQUINOLIN-3-CARBONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES COMO NEOPLASMAS, OSTEOPOROSIS, CANCER, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54651104P | 2004-02-20 | 2004-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051171A1 true PE20051171A1 (es) | 2006-02-02 |
Family
ID=34910783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000182A PE20051171A1 (es) | 2004-02-20 | 2005-02-16 | Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7449460B2 (es) |
| AR (1) | AR047709A1 (es) |
| GT (1) | GT200500030A (es) |
| PA (1) | PA8624201A1 (es) |
| PE (1) | PE20051171A1 (es) |
| SV (1) | SV2005002013A (es) |
| TW (1) | TW200529846A (es) |
| WO (1) | WO2005082891A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 |
| JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用 |
| AU2010265932B2 (en) | 2009-06-25 | 2014-11-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP2538943B1 (en) | 2010-02-25 | 2016-03-30 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| BR112012022801B8 (pt) | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| US20130079342A1 (en) * | 2010-06-30 | 2013-03-28 | Paul John Dransfield | Heterocyclic compounds and their uses |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| SG11201702041PA (en) | 2015-07-06 | 2017-04-27 | Gilead Sciences Inc | Cot modulators and methods of use thereof |
| WO2017135901A1 (en) * | 2016-02-05 | 2017-08-10 | Agency For Science, Technology And Research | Heterocyclic compounds, methods of synthesis and uses thereof |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018106184A1 (en) * | 2016-12-05 | 2018-06-14 | Agency For Science, Technology And Research | Application of multi-kinase inhibitor |
| US20220071999A1 (en) * | 2018-12-21 | 2022-03-10 | University Of Notre Dame Du Lac | Design and discovery of bd oxidase inhibitors for the treatment of mycobacterial diseases |
| TW202235416A (zh) | 2019-06-14 | 2022-09-16 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| WO2021202224A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| AU2021245924B2 (en) | 2020-04-02 | 2024-02-29 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| JP3751201B2 (ja) | 1999-02-27 | 2006-03-01 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | チロシンキナーゼにより媒介されるシグナル伝達に関する抑制効果を有する４−アミノ−キナゾリン誘導体及びキノリン誘導体 |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| PL353267A1 (en) | 1999-08-12 | 2003-11-03 | American Cyanamid Company | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| IL151249A0 (en) | 2000-03-13 | 2003-04-10 | American Cyanamid Co | Use of cyanoquinolines for treating or inhibiting colonic polyps |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| JP2004517059A (ja) | 2000-11-02 | 2004-06-10 | アストラゼネカ アクチボラグ | 抗腫瘍剤用の４−置換キノリン類 |
| US7067532B2 (en) * | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| CA2357110A1 (en) | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
-
2005
- 2005-02-03 TW TW094103382A patent/TW200529846A/zh unknown
- 2005-02-16 WO PCT/US2005/004808 patent/WO2005082891A1/en not_active Ceased
- 2005-02-16 PE PE2005000182A patent/PE20051171A1/es not_active Application Discontinuation
- 2005-02-16 US US11/059,146 patent/US7449460B2/en not_active Expired - Fee Related
- 2005-02-17 GT GT200500030A patent/GT200500030A/es unknown
- 2005-02-18 AR ARP050100597A patent/AR047709A1/es unknown
- 2005-02-18 SV SV2005002013A patent/SV2005002013A/es not_active Application Discontinuation
- 2005-02-18 PA PA20058624201A patent/PA8624201A1/es unknown
-
2008
- 2008-09-23 US US12/235,723 patent/US7767671B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR047709A1 (es) | 2006-02-08 |
| US7449460B2 (en) | 2008-11-11 |
| US20050187247A1 (en) | 2005-08-25 |
| GT200500030A (es) | 2005-10-24 |
| US20090062281A1 (en) | 2009-03-05 |
| US7767671B2 (en) | 2010-08-03 |
| PA8624201A1 (es) | 2006-06-02 |
| TW200529846A (en) | 2005-09-16 |
| SV2005002013A (es) | 2005-12-06 |
| WO2005082891A1 (en) | 2005-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051171A1 (es) | Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo | |
| PE20212069A1 (es) | Compuesto inhibidor de jak y uso del mismo | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| PE20080059A1 (es) | Quinazolinas para la inhibicion de pdk1 | |
| ES2986889T3 (es) | Compuesto pirimidina sustituido con 2,4-di-(grupo nitrogenado) y método de preparación y uso del mismo | |
| NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
| CY1108744T1 (el) | 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp | |
| PE20091728A1 (es) | Derivados de cicloheptapiridina como antagonistas de receptor de cgrp | |
| PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| PE20091849A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| NO20081581L (no) | Polymorfer av benzoatsalt av 2-[[6-[(3R)-3-amino-l-piperldinyl]-3,4-dihydro-3-metyl-2,4-diokso- 1(2H)-pyrlmidinylJmetyl)benzonitril, og fremgangsmater for anvendelse derav | |
| PE20060651A1 (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
| PE20110411A1 (es) | Imidazopiridazinacarbonitrilos como inhibidores de quinasa | |
| HRP20050059B1 (hr) | Novi inhibitori kinaza | |
| PE20081346A1 (es) | Derivados de espiroindolinona como antagonistas de mdm2 | |
| PE20040934A1 (es) | Derivados de pirimidina como inhibidores selectivos de tirosina quinasas | |
| MY145634A (en) | Pyrrolotriazine compounds as kinase inhibitors | |
| PE20060501A1 (es) | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa | |
| PE20090718A1 (es) | Derivados de espiroindolinona | |
| CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
| PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
| PE20010912A1 (es) | Derivados arilamina y su aplicacion como agentes antitelomerasa | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |